Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTHFree Report) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the stock.

Bio-Path Stock Performance

NASDAQ BPTH opened at $0.78 on Thursday. The company has a 50-day simple moving average of $0.89 and a two-hundred day simple moving average of $1.03. Bio-Path has a 12-month low of $0.59 and a 12-month high of $9.99.

Bio-Path Company Profile

(Get Free Report)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Recommended Stories

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.